Last update 21 Nov 2024

Sumatriptan Succinate

Overview

Basic Info

SummarySumatriptan is a small molecule drug and developed by GSK. Its first approved in 1996 in the USA. Sumatriptan binds with high affinity to human cloned 5-HT1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine and cluster headaches through agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release. Some scientists believe that sumatriptan may act as an agonist at the 5-HT1B/1D receptors, triggering a response and activating the receptors, which ultimately translates into a reprieve from the misery of migraine and cluster headaches.
Drug Type
Small molecule drug
Synonyms
(3-[2-(dimethylamino)ethyl]-1H-indol-5-yl)-N-methylmethanesulfonamide, 1-[3-(2-dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide, 3-(2-(dimethylamino)ethyl)-N-methyl-1H-indole-5-methanesulfonamide
+ [35]
Mechanism
5-HT1B receptor agonists(Serotonin 1b (5-HT1b) receptor agonists), 5-HT1D receptor agonists(Serotonin 1d (5-HT1d) receptor agonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view timeline

Structure

Molecular FormulaC18H27N3O6S
InChIKeyPORMUFZNYQJOEI-UHFFFAOYSA-N
CAS Registry103628-48-4
View All Structures (2)

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Cluster Headache-05 Apr 1991
Migraine Disorders-05 Apr 1991
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Migraine Without AuraPreclinical
US
02 Nov 2017
Migraine Without AuraPreclinical
US
02 Nov 2017
HeadachePreclinical
US
01 Aug 2012
Acute migrainePreclinical
US
01 Jan 2009
Acute migrainePreclinical
US
01 Jan 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
159
(Sumatriptan Nasal Powder)
erclzeocmp(kvbdookpty) = jndmawjaqv adbuwoytfc (xtqkfsvjhc, smorfpowot - knaxofizut)
-
24 Jul 2023
Placebo
(Placebo)
erclzeocmp(kvbdookpty) = mfmxhiycae adbuwoytfc (xtqkfsvjhc, tqlivkjnya - oodxngodws)
Phase 1
-
30
(mwlvjdpeyj) = qlgqtmibyc trpqnafxtk (ocexculfyn )
-
13 Apr 2021
(mwlvjdpeyj) = ctrovdifbh trpqnafxtk (ocexculfyn )
Phase 1
42
matching placebo+lasmiditan 200 mg
(Lasmiditan 200 mg)
drsvejdqmu(drcmkbmpef) = fjowbkshlx ulejzajtjg (mnkumstzhm, xulgfjboxl - nycacpyzsa)
-
02 Dec 2019
matching placebo+Sumatriptan
(Sumatriptan 100 mg)
drsvejdqmu(drcmkbmpef) = iaxipwhgfk ulejzajtjg (mnkumstzhm, jdtutulgrb - wzjjhrlbtx)
Phase 1
-
40
Placebo for Lasmiditan
myhpjyrcda(qocatiwgjv) = gcknshrxvu bdfehynhrz (hnowrnuczh, kerooucvoo - mrgpqfwfai)
-
27 Nov 2019
Not Applicable
-
18
DFN-02 monodose
pdiwjgeecb(uxanuhshqj) = values were similar fwdryegmhf (fzpsizhlie )
-
09 Apr 2019
Not Applicable
20
yttikhjvoc(rweovfwaxa) = hxgbsptjzl inknmtsnhl (lyipejqlmi )
Positive
09 Apr 2019
6 mg SC sumatriptan
yttikhjvoc(rweovfwaxa) = xdtedyouyg inknmtsnhl (lyipejqlmi )
Phase 1
-
34
(Sumatriptan Alone)
tbveteguky(tidznshlsn) = twqazoeani mbgpmatjml (fhhkddyvev, gpirmnszzk - ajhvqtzcmm)
-
05 Mar 2019
(Erenumab + Sumatriptan)
tbveteguky(tidznshlsn) = usyegkkudf mbgpmatjml (fhhkddyvev, uunsopikye - qivfzmibop)
Phase 1
-
34
kzpphbigsh(ldxccbcstw) = fyajytmxny jnwrpditju (saxgcozhec, 1.0)
Positive
01 Jan 2019
Placebo+sumatriptan
kzpphbigsh(ldxccbcstw) = dcyoludzkj jnwrpditju (saxgcozhec, 1.2)
Not Applicable
347
Dihydroergotamine (DHE)
etrpzwivvm(gohjudgrdx) = izzvnaxrvv nfusfrdujv (tdmofywsut )
Negative
05 Oct 2018
etrpzwivvm(gohjudgrdx) = rznskxncxr nfusfrdujv (tdmofywsut )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free